BBS-Bioactive Bone Substitutes Oyj: The subscription period for the second warrant series starts on 22 May 2023 – the subscription price is EUR 0.65 per share
BBS-Bioactive Bone Substitutes Oyj, Company release, 19 May 2023 at 12.00 p.m. EEST
BBS-Bioactive Bone Substitutes Oyj: The subscription period for the second warrant series starts on 22 May 2023 – the subscription price is EUR 0.65 per share
BBS-Bioactive Bone Substitutes Oyj (BBS) organized a rights issue from May 18 to June 3, 2022. In connection with the share issue, a total of 670,962 warrants from two different series (TO1 and TO2) were also granted to the subscribers. Each warrant gives its owner the right to subscribe for one new share at a discounted price.
Information about the second series of warrants (TO2):
- Subscription period: For the second warrant series (TO2), the subscription period starts on Monday 22 May 2023 and ends on Friday 2 June 2023.
- Place of subscription: The subscription place in Finland is the account and asset managers and Hagberg & Aneborn Fondkomission AB in Sweden. The subscription order must be given in accordance with the instructions given by the holder’s account administrator or asset manager.
- ISIN code: The ISIN code of the warrants (TO2) is FI4000522909.
- Subscription price: The subscription price is EUR 0.65 or SEK 7.38 per share. The share subscription price (TO2) has been determined by the volume weighted average price of the company’s share on First North Finland between 8 May 2023 and 18 May 2023, with an applied discount of 25 per cent.
- Trading: Warrants may be traded in Finland on Nasdaq First North Finland until 30 May 2023.
Terms and Conditions of Warrants TO2 are available on the Share issue 2022 website: https://www.bbs-artebone.fi/wp/wp-content/uploads/2022/05/BBS-Warrant-Plan-2-2022-TO2-20220506-FINAL.pdf
For more information:
Ilkka Kangasniemi, CEO,
tel. +358 40 708 0307, e-mail: ilkka.kangasniemi@bbs-artebone.fi
Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se
BBS in brief
BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.
BBS-Bioactive Bone Substitutes Oyj:n shares are listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
More information: www.bbs-artebone.fi
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Darca’s Educational Leadership Accelerator Addresses Shortage of School Principals30.5.2023 15:57:45 CEST | Press release
Innovative Training Program Aims to Address Shortage of School Leaders in Israeli Schools HOLON, Israel, May 30, 2023 (GLOBE NEWSWIRE) -- Darca Schools, a leading school network providing equal educational opportunities for Israel’s most underserved communities, is today well underway into the second year of its innovative training program, the Education Leadership Accelerator (ELA). This groundbreaking program fully funded by the Azrieli Foundation is part of an ongoing effort to lift Israel’s entire high school education system. “The biggest drivers of positive change in our high schools are principals, and excellent leadership is a key tenet of our successful approach. It’s clear that schools in Israel are struggling to recruit and retain exceptional leaders for these under-resourced, underappreciated and overworked roles,” said Dr. Gil Pereg, founding CEO of Darca Schools. “To fill this critical vacuum of leadership that brings about positive change, the ELA program has shown it gr
Ress Life Investment A/S announces capital increase30.5.2023 15:54:15 CEST | Press release
Ress Life Investments A/S Nybrogade 12, 1203 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 30 May 2023 Corporate Announcement 19/2023 Ress Life Investments A/S announces capital increase. The Board of Directors in Ress Life Investments A/S has today resolved to utilise its authorisation in article 4.8 of the articles of association to increase the company's share capital with nominally EUR 625,000 by issuance of 1,250 new shares with a nominal value of EUR 500 each at a price of EUR 2184.16 per share of EUR 500 without pre-emption rights for the company's existing shareholders. After the capital increase, the registered share capital of the company is EUR 84,760,500 divided into 169,521 shares of EUR 500 nominal value each. Each share of nominal EUR 500 carries one vote at general meetings in Ress Life Investments A/S. The new shares will be admitted for trading and official listing on NASDAQ Copenhagen A/S under the same ISIN code as the
Mandatory Notification of Trade30.5.2023 15:43:14 CEST | Press release
Please refer to the attached forms of notification of transaction by primary insiders under the DNO ASA Employee Synthetic Share Program. This notification has been submitted pursuant to the Norwegian Securities Trading Act § 5-12 and MAR Article 19 no. 3. Attachments Form of Notification Cash Settlement Geir Arne Skau 26 05 2023Form of Notification Cash Settlement Haakon Sandborg 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Chris Spencer 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Geir Arne Skau 26 05 2023Form of Notification Automatic Settlement of Synthetic Shares for Tax Purposes Haakon Sandborg 26 05 2023Form of Notification Cash Settlement Chris Spencer 26 05 2023
Correction: Avance Gas Holding Ltd: Key information relating to the dividend for the first quarter 202330.5.2023 15:30:30 CEST | Press release
Bermuda, May 30 2023 Please note that the record date has been included to the below key information relating to dividend for the first quarter 2023. Key information relating to the dividend to be paid by Avance Gas Holding Ltd. for the first quarter 2023: Dividend amount: $0.50 Declared currency: USD Last day including right: June 6, 2023 Ex-date: June 7, 2023 Record date: June 8, 2023 Payment date: June 14, 2023 Date of Approval: May 29, 2023 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control30.5.2023 15:30:00 CEST | Press release
Jonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost control Proposal to appoint Jonathan Milner Executive Chairman of the Board Proposal to remove Peter Allen, Michael Baldock, and Sally Crawford as Directors of the Company ExecutiveChairman Milner intends torestore Abcam to the valuation it deserves CAMBRIDGE, England, 30May 2023 – Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.3% of the Company, announced today that he has formally requisitioned the Board of Directors to convene an extraordinary general meeting of shareholders (“EGM”) to reverse a period of sustained financial and operational underperformance by providing more effective Board level leadership for the Company. The EGM will enable shareholders to vote on the following proposals: The removal of Peter Allen, Michael Baldock, and Sally Crawford from office as Directors of the